SCHEMBL9906759

SCHEMBL9906759

CCCCCCCC/C=C\CCCCCCCC(=O)NC(C)(CO)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.69
TERT O14746 3/20 0.53
PTPN1 P18031 3/20 0.53
PPARG P37231 3/20 0.53
PPARD Q03181 3/20 0.53
PPARA Q07869 3/20 0.53
MAPT P10636 2/20 0.53
BLM P54132 2/20 0.53
HSD17B10 Q99714 2/20 0.53
FABP4 P15090 2/20 0.53
KMT2A Q03164 2/20 0.53
GMNN O75496 1/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX15 P16050 1/20 0.53
APEX1 P27695 1/20 0.53
CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144284 1.00 HRH3 (0.69) HRH3TERTPTPN1PPARGPPARD
SCHEMBL1144283 1.00 HRH3 (0.69) HRH3TERTPTPN1PPARGPPARD
SCHEMBL22891559 0.94 HRH3 (0.61) HRH3TERTPTPN1PPARGPPARD
SCHEMBL9828332 0.91 HRH3 (0.54) HRH3PTPN1PPARGPPARDPPARA
SCHEMBL9828329 0.91 HRH3 (0.54) HRH3PTPN1PPARGPPARDPPARA
SCHEMBL9829055 0.85 ALDH1A1 (0.47) HRH3MAPTKMT2ANPSR1FAAH
SCHEMBL9829061 0.85 ALDH1A1 (0.47) HRH3MAPTKMT2ANPSR1FAAH
SCHEMBL16620112 0.84 HRH3 (0.66) HRH3TERTPTPN1PPARGPPARD
SCHEMBL16620111 0.84 HRH3 (0.66) HRH3TERTPTPN1PPARGPPARD
SCHEMBL7739091 0.82 HRH3 (1.00) HRH3TERTPTPN1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000814-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2022-01-06 US disclosed
US-20220000814-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2022-01-06 US disclosed
US-11058652-B2 Methods for treatment of Prader-Willi syndrome YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2021-07-13 US disclosed
US-11058652-B2 Methods for treatment of Prader-Willi syndrome YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2021-07-13 US disclosed
EP-3432874-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2021-01-13 EP disclosed
EP-3432874-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2021-01-13 EP disclosed
US-20190151264-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-05-23 US disclosed
US-20190151264-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-05-23 US disclosed
EP-3432874-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2019-01-30 EP disclosed
WO-2017179058-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-10-19 WO disclosed
WO-2017179058-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-10-19 WO disclosed
US-8198327-B2 Fatty acid amides and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-06-12 US disclosed
US-8198327-B2 Fatty acid amides and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-06-12 US disclosed
US-20110046222-A1 FATTY ACID AMIDES AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2011-02-24 US disclosed
US-20110046222-A1 FATTY ACID AMIDES AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2011-02-24 US disclosed
WO-2009125409-A2 FATTY ACID AMIDES AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046222-A1 FATTY ACID AMIDES AND USES THEREOF FASN, FADS1, ELOVL5 HRH3 601/4885TERT 4315/4885PTPN1 4384/4885
US-20190151264-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME EBP, MECP2, PRKD3 HRH3 2365/4885TERT 4258/4885PTPN1 3202/4885
US-20220000814-A1 METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME MECP2, BHMT2, EBP HRH3 2188/4885TERT 4323/4885PTPN1 2659/4885
US-11058652-B2 Methods for treatment of Prader-Willi syndrome EBP, MECP2, PRKD3 HRH3 2365/4885TERT 4258/4885PTPN1 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.